Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025

Nurix Therapeutics, Inc.

ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.
Median duration of response not reached; 13 patients >6 months, 5 >1 year on treatment.
Well tolerated; only 1 grade 1 atrial fibrillation; common AEs: purpura/contusion, fatigue, petechiae, neutropenia.
Responses across baseline BTK (38.6%), PLCG2 (12.3%), TP53 (40.4%) mutations and CNS involvement (5 patients).
Company on track to initiate pivotal trials of NX-5948 in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.